Global Animal Model Market Outlook, 2029

The global animal model market has a rich history that dates back to early scientific research, where animals were used to understand biological processes and disease mechanisms. Initially, animal models were primarily used in basic research to explore fundamental biological principles, but their role has expanded significantly over the decades. Today, animal models are crucial in preclinical testing for drug development, medical research, and toxicology studies, playing an indispensable role in advancing human health and medicine. The culture of the market is deeply rooted in ethical considerations, scientific advancement, and regulatory compliance, reflecting a commitment to balancing research benefits with animal welfare. The competitive landscape is dominated by leading players such as Charles River Laboratories, Envigo, and Jackson Laboratory, who are renowned for their comprehensive portfolios of genetically modified, disease-specific, and traditional animal models. These companies continuously innovate to provide high-quality and reliable models to meet the growing demands of research and pharmaceutical industries. Interesting facts about the market include the increasing use of genetically modified animals to model human diseases more accurately, and the growing trend towards using alternative methods like in vitro models and computer simulations to complement animal testing. Government regulations play a crucial role in the market, with stringent guidelines enforced by entities such as the U.S. Animal Welfare Act and the European Union’s Directive 2010/63/EU, which govern the ethical treatment and use of animals in research. These regulations mandate rigorous standards for animal housing, care, and experimental procedures, ensuring that the use of animal models is both humane and scientifically valid. Key developments in the market include advancements in genetic engineering, which have led to the creation of more precise and relevant animal models, and the increasing integration of 3D bioprinting technologies. These innovations are enhancing the efficacy and scope of animal models, supporting the ongoing evolution of biomedical research and drug discovery.


According to the research report, “Global Animal Model Market Outlook, 2029” published by Bonafide Research, the market is expected to reach USD 2.20 Billion by 2023. The global animal model market is experiencing robust growth driven by advancements in biomedical research and an increasing demand for preclinical testing. Influencing factors include the rise in chronic diseases and the continuous need for novel therapies, which propel the demand for accurate and reliable animal models. Market players are employing strategies such as investing in genetic modification technologies and expanding their portfolios to include a wider range of disease models and species. Special aspects of the market include the development of genetically engineered models, which offer more precise simulations of human diseases, and the growing emphasis on ethical considerations and alternative testing methods. Interesting facts about the market highlight the integration of 3D bioprinting and in silicon modelling technologies, which complement traditional animal testing by providing additional insights and reducing the number of animals needed. Furthermore, international regulations and guidelines are increasingly shaping the market, enforcing higher standards for animal welfare and experimental practices, and driving innovation towards more humane and effective research methods. This dynamic landscape underscores the critical role of animal models in advancing medical science while balancing ethical concerns and regulatory requirements.

Market Drivers

• Rising Demand for Novel Therapies and Drugs: The global animal model market is significantly driven by the increasing need for new and effective therapies and drugs. As chronic diseases, such as cancer, diabetes, and cardiovascular conditions, continue to rise, there is a pressing need for extensive preclinical testing to develop and validate new treatments. Animal models play a crucial role in this process by providing essential data on the efficacy and safety of experimental drugs before they proceed to human trials. This heightened demand for novel therapeutic solutions fuels investments in advanced animal models, including genetically modified and disease-specific models, which can more accurately replicate human conditions and accelerate the drug development process. Pharmaceutical and biotechnology companies are continuously seeking innovative animal models to streamline their research and development efforts, driving growth in the animal model market.
• Advancements in Genetic Engineering and Biotechnology: Technological advancements in genetic engineering and biotechnology are another significant driver of the animal model market. Innovations such as CRISPR-Cas9 gene editing and the creation of transgenic and knockout models have revolutionized the ability to study complex diseases and test potential treatments with high precision. These advanced models enable researchers to manipulate specific genes and observe their effects on disease progression, offering valuable insights into human health conditions. The development of genetically modified animals, such as humanized mice, has become increasingly important in studying human-specific diseases and evaluating drug responses. The continuous advancement of these technologies supports the growing demand for sophisticated animal models, driving the market forward.

Market Challenges



• Ethical Concerns and Regulatory Compliance: One of the major challenges facing the animal model market is the ethical concerns surrounding the use of animals in research. Public awareness and advocacy for animal welfare have led to increased scrutiny and pressure on researchers and companies to ensure humane treatment of animals. Compliance with stringent regulations, such as the U.S. Animal Welfare Act and the European Union’s Directive 2010/63/EU, requires significant resources and rigorous adherence to ethical standards. These regulations mandate detailed documentation of animal care, housing conditions, and experimental procedures, which can be complex and costly to manage. Balancing the need for scientific progress with ethical considerations and regulatory requirements poses a substantial challenge for stakeholders in the animal model market.
• High Costs and Resource Intensiveness: The high costs associated with developing and maintaining animal models present another challenge in the market. Creating and housing genetically modified animals, as well as conducting long-term studies, can be financially burdensome. Additionally, the need for specialized facilities, skilled personnel, and ongoing maintenance further increases operational costs. Smaller research institutions and biotechnology companies may find it challenging to afford these expenses, potentially limiting their ability to access advanced animal models. The high resource intensiveness required for animal model research can impact the overall affordability and accessibility of preclinical testing, posing a challenge for market growth.

Market Trends

• Integration of Alternative Testing Methods: A notable trend in the animal model market is the growing integration of alternative testing methods, such as in vitro models, organ-on-a-chip technologies, and computational simulations. These alternatives aim to complement traditional animal testing by providing additional insights and reducing the reliance on animal models. For example, organ-on-a-chip technologies mimic human organ systems and allow researchers to study disease mechanisms and drug responses without using live animals. Similarly, in silico modeling can predict the effects of drugs based on computational simulations, offering valuable preliminary data. The adoption of these alternative methods reflects a shift towards more ethical and efficient research practices while supporting the ongoing refinement of animal models.
• Focus on Personalized Medicine and Humanized Models: The focus on personalized medicine is driving the demand for more humanized animal models that can better replicate individual genetic variations and disease profiles. Humanized animal models, such as mice with human immune systems or tissues, offer enhanced relevance for studying human-specific diseases and testing personalized treatments. This trend aligns with the growing emphasis on precision medicine, which seeks to tailor treatments based on individual genetic and molecular profiles. By incorporating human genetic material into animal models, researchers can gain deeper insights into how specific genetic factors influence disease and treatment outcomes, ultimately advancing the development of personalized therapies. This trend underscores the importance of developing advanced and relevant animal models to meet the evolving needs of modern biomedical research.

Based on the report, the application segment is distinguished into Drug discovery and development, Basic research and Others.

The global animal model market is integral to numerous facets of biomedical research and therapeutic development, serving a diverse range of applications that underpin advancements in science and medicine. At the forefront of this market is drug discovery and development, where animal models play a crucial role in assessing the safety, efficacy, and pharmacokinetics of new pharmaceuticals. These models provide essential data on how potential drugs interact with biological systems, helping researchers identify promising candidates and predict possible side effects before clinical trials in humans. This rigorous preclinical testing is fundamental to advancing new therapies and ensuring that drugs are safe and effective. Beyond drug development, animal models are indispensable in basic research, where they facilitate the exploration of fundamental biological processes, genetic functions, and disease mechanisms. By allowing scientists to study gene functions, cellular processes, and the effects of environmental factors on health, these models contribute to the foundational knowledge needed for breakthroughs in various fields, including genetics, immunology, and neurology. These core applications, animal models are vital for toxicology testing, where they are used to evaluate the potential toxicity of chemicals, pharmaceuticals, and environmental agents. This testing helps determine safe exposure levels and identify any adverse effects, ensuring that new substances do not pose significant health risks. Animal models are also employed in preclinical testing for medical devices, such as implants and diagnostic tools, where they help assess the safety, performance, and biocompatibility of these devices before they are tested in humans. This application is critical for obtaining regulatory approvals and bringing innovative technologies to market. The focus on genetic and disease modeling has led to the development of animal models that replicate specific human genetic disorders and disease conditions, providing valuable insights into disease mechanisms and aiding in the development of targeted therapies. Behavioural studies using animal models explore the impact of genetic, environmental, and pharmacological factors on behavior and cognition, contributing to the understanding and treatment of mental health disorders. Regenerative medicine and stem cell research utilize animal models to investigate the potential of stem cells for tissue repair and regeneration, advancing treatments for degenerative diseases and injuries. The diverse applications of animal models highlight their essential role in advancing medical science, ensuring the safety and efficacy of new treatments, and supporting a wide range of research initiatives. As research techniques and technologies evolve, the applications of animal models continue to expand, underscoring their importance in driving innovation and improving human health.

North America's leadership in the animal model industry is primarily due to its advanced research infrastructure, extensive investment in biomedical research, and robust regulatory framework.

North America's dominance in the animal model industry can be attributed to several interrelated factors that collectively establish it as the leading region globally. One of the primary reasons for this leadership is the region's advanced research infrastructure. North America, particularly the United States and Canada, boasts a network of world-class research institutions, universities, and pharmaceutical companies that are at the forefront of scientific and medical research. Institutions such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) in the United States, along with renowned universities like Harvard, Stanford, and the University of Toronto, are pivotal in driving research and development in the animal model industry. These institutions provide not only the necessary facilities but also foster collaborations and innovations that propel the industry forward. North America's significant investment in biomedical research plays a crucial role in maintaining its leadership position. The region allocates substantial funding towards research and development in various fields, including drug discovery, disease modelling, and therapeutic development. This financial support facilitates the creation and use of diverse and sophisticated animal models, which are essential for understanding complex biological processes and evaluating new treatments. The presence of major pharmaceutical and biotechnology companies in North America further enhances this investment landscape, as these companies rely heavily on animal models to validate their research and accelerate the development of new drugs and therapies. The regulatory framework in North America also contributes to the region's leadership in the animal model industry. Both the United States and Canada have established comprehensive and well-regulated systems for the ethical use of animals in research. Regulatory bodies such as the Food and Drug Administration (FDA) and the Canadian Council on Animal Care (CCAC) set stringent guidelines and standards for the use of animal models, ensuring that research is conducted responsibly and ethically. This regulatory environment not only supports high-quality research but also builds trust with the public and stakeholders, fostering a favorable climate for continued investment and innovation. North America's strong emphasis on collaborative research and public-private partnerships further supports its leadership in the animal model industry. Collaborations between academic institutions, government agencies, and industry players facilitate the sharing of knowledge, resources, and technology.

Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in this report
• Animal Model market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Animal Type
• Rat
• Mice
• Guinea pigs
• Rabbits
• Others

By Application
• Drug discovery and development
• Basic research
• Others

By End User
• Pharma and biotech companies
• Academic research institutes
• Others

The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Animal Model industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.